The peptide ghrelin receptor antagonist d-Lys-3-GHRP-6 dose-dependently impaired both memory acquisition and consolidation when injected into the rat brain.
Dose-dependent memory impairmentBoth pre-training and post-training ghrelin receptor blockade impaired memory in a passive avoidance task, with effects scaling with antagonist dose
What the researchers found
Blocking ghrelin receptors (GHS-R1a) in the rat brain with the peptide antagonist d-Lys-3-GHRP-6 impaired memory encoding in a dose-dependent manner. Post-training injection significantly decreased step-through latency, increased time spent in the dark compartment, and increased the number of entries into the dark compartment — all indicating impaired memory consolidation.
Pre-training injection also impaired memory acquisition, significantly increasing time in the dark compartment in a dose-dependent manner. These results demonstrate that ghrelin receptor signaling in the brain is involved in both the acquisition and consolidation stages of memory formation.
Why it matters
Ghrelin is known primarily as a hunger hormone, but this study adds to growing evidence that the ghrelin-GHSR signaling pathway plays an important role in cognitive function. Understanding how peptide hormones like ghrelin influence memory could lead to new therapeutic targets for memory disorders and provides insight into why metabolic status affects cognitive performance.
How the study worked
72 male Wistar rats (230-280g) were divided into 9 groups of 8. After stereotaxic surgery to implant cannulas in the right ventricle, rats received intracerebroventricular (i.c.v.) injections of the GHS-R1a antagonist d-Lys-3-GHRP-6 at various doses (0.2, 2, 20, and 80 nM/5μl) either 10 minutes before training (acquisition) or immediately after training (consolidation) in a passive avoidance task. Memory retrieval was tested 24 hours later. Controls received drug solvent.
Who was studied
72 male Wistar rats (230-280g), 9 groups of 8
What this study cannot tell us
This is a rodent study using direct brain injection, which has limited clinical translatability. The passive avoidance task tests only one type of memory (fear-motivated learning). The study did not identify which specific brain regions mediate the effect. The 2015 publication date means more recent work may have advanced understanding of this pathway.
How to read the evidence
This is a preliminary-grade animal study with a well-controlled design (72 rats, multiple dose groups, both acquisition and consolidation testing) but limited to a single behavioral paradigm and direct brain injection in rodents.
When this study was published
Published in 2015, this study established foundational evidence for ghrelin's role in memory. More recent research has likely expanded on these findings with additional brain regions and behavioral tests.
The bigger picture
This study contributes to a growing body of research showing that metabolic peptide hormones like ghrelin have cognitive functions beyond appetite regulation. The finding that ghrelin receptor blockade impairs memory connects to broader questions about why fasting states (when ghrelin is high) may enhance certain types of learning, and why metabolic disorders like obesity and diabetes are associated with cognitive decline.
Questions still open
- Which specific brain regions (hippocampus, amygdala, cortex) mediate ghrelin's effects on memory formation?
- Could ghrelin or ghrelin receptor agonists be developed as memory-enhancing therapies for age-related cognitive decline?
- Do the cognitive effects of GHS-R1a blockade have implications for the safety profile of anti-obesity drugs targeting the ghrelin system?
Common questions
What is ghrelin and what does it do in the brain?
What is d-Lys-3-GHRP-6 and how does it relate to ghrelin?
Read the original research
Blocking the ghrelin receptor type 1a in the rat brain impairs memory encoding.
Neuropeptides, 52, 97-102
Citation
Beheshti, Siamak; Shahrokhi, Shahrzad. (2015). Blocking the ghrelin receptor type 1a in the rat brain impairs memory encoding.. Neuropeptides, 52, 97-102. https://doi.org/10.1016/j.npep.2015.05.003